Skip to main content
Signal8

CSO of Napo Pharmaceuticals, a Jaguar Health Family Company, and Clinical Investigators Evaluating Crofelemer Conduct Panel Discussion at Pediatric Gastroenterology Conference in Dubai (UAE)

$JAGXPress releaseNov 2, 2026, 9:00 AM ETRead the release

Jaguar Health's subsidiary Napo Pharmaceuticals recapped a panel at the 2nd Best of Elite Ped-GI meeting in Dubai, where its CSO and clinical investigators discussed pediatric intestinal failure and crofelemer. Panelists reviewed data from pediatric MVID and SBS-IF patients on liquid oral crofelemer for over a year, showing reduced parenteral support normalized to body weight and improved weight and stature growth parameters.

Key figures

Drug Name
crofelemer (liquid oral formulation / powder for oral solution)
Dosing duration
>1 year of liquid oral crofelemer in pediatric MVID and SBS-IF patients
Nda filing target
mid-2027

AI analysis

Red flags1 · Pro

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.